Shire PLC (SHP.L) Quote| Reuters.com
Edition:
United States

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,350.00GBp
4:43am EDT
Change (% chg)

106.00p (+2.50%)
Prev Close
4,244.00p
Open
4,296.00p
Day's High
4,355.00p
Day's Low
4,286.00p
Volume
457,135
Avg. Vol
2,825,704
52-wk High
5,870.00p
52-wk Low
3,423.00p

SHP.L

Chart for SHP.L

About

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.... (more)

Overall

Beta: 1.13
Market Cap(Mil.): £37,787.07
Shares Outstanding(Mil.): 898.57
Dividend: 15.32
Yield (%): --

Financials

  SHP.L Industry Sector
P/E (TTM): 24.94 33.26 34.67
EPS (TTM): 1.69 -- --
ROI: 8.21 14.89 14.11
ROE: 13.84 15.96 15.33

BRIEF-Shire and Kamada announce FDA approval of an expanded label for GLASSIA

* Shire and Kamada announce FDA approval of expanded label for self-infusion of GLASSIA for the treatment of emphysema due to severe AAT deficiency

Jun 15 2016

Shire buys bowel drug rights from Pfizer

Irish drugmaker Shire Plc said it would buy the rights to an experimental bowel drug from Pfizer Inc to bolster its pipeline of gastrointestinal treatments.

Jun 14 2016

UPDATE 1-Shire buys bowel drug rights from Pfizer

June 14 Irish drugmaker Shire Plc said it would buy the rights to an experimental bowel drug from Pfizer Inc to bolster its pipeline of gastrointestinal treatments.

Jun 14 2016

Drugmaker Shire buys bowel drug rights from Pfizer

June 14 Irish drugmaker Shire Plc said on Tuesday it would buy from Pfizer Inc the rights to an experimental drug, designed to treat moderate-to-severe inflammatory bowel disease.

Jun 14 2016

BRIEF-Shire to license investigational gastric drug from Pfizer

* Shire to license PF-00547659 from Pfizer, adding to established and leading gastrointestinal portfolio

Jun 14 2016

BRIEF-Shire receives FDA breakthrough therapy designation

* Granted breakthrough therapy designation for two investigational products for rare diseases: SHP621 and SHP625

Jun 13 2016

BRIEF-Baxalta shareholders vote to approve combination

* Baxalta says shareholders approved merger agreement with Shire with about 76.9 percent of shares outstanding cast in favor of proposal

May 27 2016

BRIEF-Baxalta shareholders vote to approve combination

* Shareholders approved definitive merger agreement with Shire with approximately 98.9 percent of shares outstanding cast in favor of proposal Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 27 2016

BRIEF-Baxalta announces preliminary merger consideration election results

* Baxalta announces preliminary merger consideration election results

May 23 2016

Shire jumps as Vyvanse drug helps it to beat earnings forecast

LONDON Strong demand for Shire's top-selling Vyvanse drug helped to lift first-quarter earnings by a better than expected 12 percent, boosting the London-listed group's shares ahead of its $32 billion acquisition of U.S. rare diseases specialist Baxalta .

Apr 29 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.